Skip to main content
Figure 4 | Malaria Journal

Figure 4

From: The initial pharmaceutical development of an artesunate/amodiaquine oral formulation for the treatment of malaria: a public-private partnership

Figure 4

Tablet AS and DHA content of ASAQ monolayer tablets, after 3 months at 40°C/75%RH blistered. Key: AS = artesunate; DHA = dihydroartesunate; black dotted lines: specifications of AS content (100 ± 5 mg/tablet). Mean of 10.AS content in black, on the left Y axis; DHA content in grey, on the right Y axis Tablet formulations are summarized in the table under histogrammes.

Back to article page

Malaria Journal

ISSN: 1475-2875

Contact us